BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37703603)

  • 1. AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8
    Im K; Choi YJ; Kim DH; Kim DS; Ban K; Ji W; Baek IJ; Choi CM; Lee JC; Rho JK
    Biochem Biophys Res Commun; 2023 Nov; 680():7-14. PubMed ID: 37703603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
    Fu C; Jiang A
    Front Immunol; 2018; 9():3059. PubMed ID: 30619378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
    Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
    Front Immunol; 2022; 13():869676. PubMed ID: 35572601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC9 deficiency promotes tumor progression by decreasing the CD8
    Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.
    Zhao K; Jiang L; Si Y; Zhou S; Huang Z; Meng X
    Cancer Immunol Immunother; 2023 Jan; 72(1):193-209. PubMed ID: 35794399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
    Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
    Front Immunol; 2018; 9():2775. PubMed ID: 30542351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo.
    Subramanian M; Hayes CD; Thome JJ; Thorp E; Matsushima GK; Herz J; Farber DL; Liu K; Lakshmana M; Tabas I
    J Clin Invest; 2014 Mar; 124(3):1296-308. PubMed ID: 24509082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.
    Guo Z; Li Y; Zhang D; Ma J
    Oncotarget; 2017 Oct; 8(52):89761-89774. PubMed ID: 29163786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Batf3-Dependent Dendritic Cells Promote Optimal CD8 T Cell Responses against Respiratory Poxvirus Infection.
    Desai P; Tahiliani V; Abboud G; Stanfield J; Salek-Ardakani S
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
    O'Melia MJ; Manspeaker MP; Thomas SN
    Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
    Salmon H; Idoyaga J; Rahman A; Leboeuf M; Remark R; Jordan S; Casanova-Acebes M; Khudoynazarova M; Agudo J; Tung N; Chakarov S; Rivera C; Hogstad B; Bosenberg M; Hashimoto D; Gnjatic S; Bhardwaj N; Palucka AK; Brown BD; Brody J; Ginhoux F; Merad M
    Immunity; 2016 Apr; 44(4):924-38. PubMed ID: 27096321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXL targeting restores PD-1 blockade sensitivity of
    Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
    Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
    Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
    Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
    Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
    J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
    Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
    Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node.
    Kitano M; Yamazaki C; Takumi A; Ikeno T; Hemmi H; Takahashi N; Shimizu K; Fraser SE; Hoshino K; Kaisho T; Okada T
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):1044-9. PubMed ID: 26755602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.